REporting recommendations for tumor MARKer prognostic studies (REMARK)
Top Cited Papers
- 1 August 2005
- journal article
- guideline
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 2 (8) , 416-422
- https://doi.org/10.1038/ncponc0252
Abstract
Despite the plethora of reports on tumor markers in oncology, the number of markers that have emerged as clinically useful is disappointing. There is considerable evidence that the quality of reporting of studies of biomarkers, particularly tumor prognostic markers, is generally poor. McShaneet al. present guidelines that provide helpful suggestions on study design, patient characteristics, statistical analysis methods, and guidance on how to present data. The authors advocate the importance of transparent and complete reporting of tumor marker prognostic studies in order to increase accessibility and interpretability of trial data, which should help to improve patient treatment and management. Despite years of research and hundreds of reports on tumor markers in oncology, the number of markers that have emerged as clinically useful is pitifully small. Often initially reported studies of a marker show great promise, but subsequent studies on the same or related markers yield inconsistent conclusions or stand in direct contradiction to the promising results. It is imperative that we attempt to understand the reasons why multiple studies of the same marker lead to differing conclusions. A variety of methodological problems have been cited to explain these discrepancies. Unfortunately, many tumor marker studies have not been reported in a rigorous fashion, and published articles often lack sufficient information to allow adequate assessment of the quality of the study or the generalizability of study results. The development of guidelines for the reporting of tumor marker studies was a major recommendation of the National Cancer Institute–European Organisation for Research and Treatment of Cancer (NCI–EORTC) First International Meeting on Cancer Diagnostics in 2000. As for the successful CONSORT initiative for randomized trials and for the STARD statement for diagnostic studies, we suggest guidelines to provide relevant information about the study design, preplanned hypotheses, patient and specimen characteristics, assay methods, and statistical analysis methods. In addition, the guidelines provide helpful suggestions on how to present data and important elements to include in discussions. The goal of these guidelines is to encourage transparent and complete reporting so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.boxed-textKeywords
This publication has 39 references indexed in Scilit:
- A Systematic Review of Molecular and Biological Tumor Markers in NeuroblastomaClinical Cancer Research, 2004
- Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the futureBritish Journal of Cancer, 2003
- Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD InitiativeClinical Chemistry, 2003
- A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma familyEuropean Journal Of Cancer, 2003
- Potential for Selection Bias with Tumor Tissue Retrieval in Molecular Epidemiology StudiesAnnals of Epidemiology, 2002
- Sensitivity of HER-2/neu Antibodies in Archival Tissue Samples of Invasive Breast CarcinomasAmerican Journal of Clinical Pathology, 2000
- Predicting the future: a critical appraisal of cancer prognosis studiesHistopathology, 1999
- Dangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic FactorsJNCI Journal of the National Cancer Institute, 1994
- Criteria for prognostic factors and for an enhanced prognostic systemCancer, 1993
- Why do so many prognostic factors fail to pan out?Breast Cancer Research and Treatment, 1992